GKB Ophthalmics Limited (GKB) Fair Value & Analysis
Healthcare · IN · Market cap ₹318M
Fair value as of: Jul 5, 2026
From 17 valuation models · updated today
Share price −0.9% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹47.26 – ₹84.90 · fair‑value band ₹39.89 – ₹66.48 · the ₹63.11 price screens above the ₹56.79 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
GKB Ophthalmics Limited (GKB) currently trades at ₹63.11, while our model-based Fair Value estimate is ₹56.79 — implying the stock looks roughly 10.0% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, GKB Ophthalmics Limited generated revenue of ₹1.5B at a net margin of 0.8%. Revenue declined 4.0% year over year. It earns a return on equity of 5.4%. Net debt stands at ₹89.9M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹39.89 (bear case) to ₹66.48 (bull case); at ₹63.11, the current price sits within that range. The share trades about 31% below its 52-week high and 39% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside — at -10%, GKB screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
GKB Ophthalmics Limited manufactures and sells ophthalmic lenses in India and internationally. It offers finished and semi-finished glass and plastic lenses. The company was founded in 1981 and is based in Mapusa, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
GKB Ophthalmics Limited reported revenue of ₹1.5B in FY2026 versus ₹709M in FY2022, a compound +20.4%/yr. Reported net income was ₹12.2M in FY2026, compounding −1.1%/yr from FY2022.
Is GKB fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $422.06 | $165.35 | -61% |
| EssilorLuxottica Société anonyme ESLOF | $205.86 | $114.90 | -44% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
| ResMed Inc R1MD34 | R$253.26 | R$41.40 | -84% |
| West Pharmaceutical Services, Inc WST | $329.71 | $137.28 | -58% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $12.68 | $5.49 | -57% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GKB Ophthalmics Limited (GKB) undervalued?
What is the fair value of GKB?
What is the quality score of GKB?
What is the revenue of GKB Ophthalmics Limited (GKB)?
What is the net profit margin of GKB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.